Drug Search Results
More Filters [+]

Lacripep

Alternative Names: lacripep
Latest Update: 2023-07-01
Latest Update Note: PubMed Publication

Product Description

Lacripep, which is derived from the Lacritin protein, is a first-in-class topical therapy that preserves all of Lacritin’s bioactivity. (Sourced from: https://tearsolutions.com)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Ophthalmic

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: TearSolutions
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lacripep

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Keratoconjunctivitis Sicca|Dry Eye Syndromes|Sjogren's Syndrome

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

LOS-001

P2

Completed

Keratoconjunctivitis Sicca|Sjogren's Syndrome|Dry Eye Syndromes

2019-12-27

24%

Recent News Events